NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: VIVIMEDLAB · data 2026-11-01
Vivimed Labs Limited
In plain words
Price: 81.2% below its 52-week high of ₹29.4.
Delivery: 85.5% of traded shares were kept for delivery over the last 10 sessions, against 76.9% over the last 45.
Latest results: a net loss of ₹146 cr for the quarter ended Mar 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹70 cr |
| Net profit (last 12 months) | ₹-176 cr |
| Sales growth, 3 years (yearly) | -27.9% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 7.6% (-13.4 pts in a year), pledged 15.2%, institutions 1.6%.
ROE —, ROCE -43.6%, operating margin -255.0%: how much profit it earns on the money it uses.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Thin operating margin (-255.0%).
- Promoters have pledged 15.2% of their shares.
- Promoters cut their holding by 13.4 points in a year.
- Reported a loss in the latest quarter.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q4 FY26)
VIVIMEDLAB Q4 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹12 crore, down 53.1% YoY and down 25% QoQ.
Net loss was ₹146.03 crore, a bigger loss than a year ago and a bigger loss than last quarter.
Operating margin was 1,159.9% (7.8% a year ago).
EPS was -₹17.74, more negative than a year ago and more negative than last quarter.
VIVIMEDLAB के Q4 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹12 करोड़; पिछले साल की तुलना में 53.1% की गिरावट, पिछली तिमाही की तुलना में 25% की गिरावट।
शुद्ध घाटा: ₹146.03 करोड़; एक साल पहले से घाटा बढ़ा, पिछली तिमाही से घाटा बढ़ा।
ऑपरेटिंग मार्जिन: 1,159.9% (एक साल पहले 7.8%)।
EPS: -₹17.74; एक साल पहले से अधिक ऋणात्मक, पिछली तिमाही से अधिक ऋणात्मक।
VIVIMEDLABના Q4 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹12 કરોડ; ગયા વર્ષની સરખામણીએ 53.1% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 25% ઘટાડો.
ચોખ્ખી ખોટ: ₹146.03 કરોડ; એક વર્ષ પહેલાંની સરખામણીએ ખોટ વધી, ગયા ક્વાર્ટરની સરખામણીએ ખોટ વધી.
ઓપરેટિંગ માર્જિન: 1,159.9% (એક વર્ષ પહેલાં 7.8%).
EPS: -₹17.74; એક વર્ષ પહેલાંના કરતાં વધુ નકારાત્મક, ગયા ક્વાર્ટરના કરતાં વધુ નકારાત્મક.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 17 Jul 26Results Q4 FY26 results: loss widened vs a year ago +3.5% next session
- 13 Mar 26Results Q3 FY26 results: loss widened vs a year ago -5.0% next session
- 14 Nov 25Results Q2 FY26 results: loss widened vs a year ago
- 14 Aug 25Results Q1 FY26 results: loss narrowed vs a year ago
- 21 Jul 25Results Q4 FY25 results: turned to loss vs a year ago
- 15 Feb 25Results Q3 FY25 results: loss narrowed vs a year ago
- 17 Jan 25Results Q2 FY25 results: loss narrowed vs a year ago
- 16 Jan 25Results Q1 FY25 results: loss narrowed vs a year ago
- 15 Nov 24Results Q4 FY24 results: turned to profit vs a year ago
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Mar 2026 | ₹12 cr | ₹-146 cr | — | -1159.9% | -17.74 |
| Dec 2025 | ₹16 cr | ₹-17 cr | — | -68.3% | -0.88 |
| Sept 2025 | ₹21 cr | ₹-7 cr | — | -4.6% | -0.88 |
| Jun 2025 | ₹21 cr | ₹-5 cr | — | -1.3% | -0.66 |
Shareholding trend
| Holder | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 |
|---|---|---|---|---|
| Promoters | 7.57% | 7.77% | 7.77% | 7.77% |
| Foreign institutions (FII) | 1.64% | 1.64% | 1.64% | 1.64% |
| Domestic institutions (DII) | 0.00% | 0.00% | — | — |
| Mutual funds | 0.00% | 0.00% | — | — |
| Retail investors | 57.49% | 57.34% | 57.45% | 57.46% |
| Number of shareholders | 47,492 | 49,221 | 48,925 | 48,928 |
Common questions
What was Vivimed Labs Limited's latest quarterly profit?
Vivimed Labs Limited reported a net loss of ₹146 cr for the quarter ended Mar 2026, on revenue of ₹12 cr.
How much do promoters hold in Vivimed Labs Limited?
Promoters held 7.57% of Vivimed Labs Limited at the end of Mar 2026, with 15.18% of promoter shares pledged.
What is the 52-week high and low of Vivimed Labs Limited?
The 52-week high is ₹29.4 and the 52-week low is ₹4.75.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Vivimed Labs Limited | ₹5.53 | ₹51 cr | — | — | — | -43.6% | — | +5.3% |
| Onyx Biotec Ltd. | ₹36 | ₹65 cr | — | — | -0.4% | 0.5% | 0.27 | -12.4% |
| Zenith Drugs Ltd. | ₹37 | ₹63 cr | 16.1 | 0.9 | 5.5% | 9.3% | 0.75 | -40.5% |
| Biofil Chemicals & Pharmaceuticals Ltd. | ₹28.68 | ₹47 cr | 96.4 | — | 13.8% | 1.8% | 0.14 | -27.5% |
| Mangalam Drugs & Organics Ltd. | ₹28.61 | ₹46 cr | — | — | -35.2% | -22.8% | 1.08 | -58.2% |
| Medicamen Organics Ltd. | ₹26.5 | ₹39 cr | — | — | -13.7% | -15% | 0.5 | -24.6% |
Compare VIVIMEDLAB with ONYX in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open VIVIMEDLAB in NSE Scanner →